Information  X 
Enter a valid email address

Nuformix PLC Ord 0.1P (NFX)

Related News

22-Dec-2020 09:28 AM

Nuformix posts loss, continues Asian licensing talks

Drug re-purposing specialist Nuformix posted a first-half loss as its revenue fell. Pre-tax losses for the six months through September amounted to £0.48 million, compared to losses of £0.13 million year-on-year. Revenue dropped to £0.
24-Dec-2019 09:17 AM

Nuformix reaches milestone with lead product

Drugs developer Nuformix successfully completed its first clinical development study for its lead product NXP001 in the six months to 30 September. In its half year results, the company added that additional out-licensing and development opportunities fo
15-Dec-2017 08:20 AM

Broker Forecast - Beaufort Securities issues a broker note on Nuformix Plc Ord 0.1p

Beaufort Securities today initiates coverage of Nuformix Plc Ord 0.1p (LON:NFX) with a speculative buy investment rating and price target of 5p. Story provided by
19-Oct-2017 09:53 AM

Nuformix signs agreement with Quotient Clinical

Nuformix, a pharmaceutical development company, has signed an agreement with Quotient Clinical to conduct a pilot bioequivalence study for one of its lead programmes, NXP001, based on a currently marketed treatment in the field of oncology supportive care
Top categories
Company finder

a d v e r t i s e m e n t